BIIB

BIIB

USD

Biogen Inc. Common Stock

$124.990-4.560 (-3.520%)

Precio en Tiempo Real

Healthcare
Drug Manufacturers - General
Estados Unidos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado
Fundamentos de la Empresa
Estadísticas de Negociación

Métricas de Mercado

Apertura

$129.550

Máximo

$129.580

Mínimo

$124.680

Volumen

1.14M

Fundamentos de la Empresa

Capitalización de Mercado

18.3B

Industria

Drug Manufacturers - General

País

United States

Estadísticas de Negociación

Volumen Promedio

1.48M

Bolsa

NMS

Moneda

USD

Rango de 52 Semanas

Mínimo $110.04Actual $124.990Máximo $236.48

Noticias Relacionadas

GlobeNewswire

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy

Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults with primary membranous nephropathy (PMN)There are currently no therapies specifically approved

Ver más
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
GlobeNewswire

New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA

New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg SPINRAZA®

Ver más
New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA
Analyst Upgrades

RBC Capital Reiterates Outperform on Biogen, Maintains $213 Price Target

RBC Capital analyst Brian Abrahams reiterates Biogen with a Outperform and maintains $213 price target.

Ver más
RBC Capital Reiterates Outperform on Biogen, Maintains $213 Price Target
Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on Biogen, Maintains $187 Price Target

HC Wainwright & Co. analyst Andrew Fein reiterates Biogen with a Buy and maintains $187 price target.

Ver más
HC Wainwright & Co. Reiterates Buy on Biogen, Maintains $187 Price Target
GlobeNewswire

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show children with SMA

Ver más
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
Analyst Upgrades

Piper Sandler Reiterates Neutral on Biogen, Maintains $115 Price Target

Piper Sandler analyst David Amsellem reiterates Biogen with a Neutral and maintains $115 price target.

Analyst Upgrades

Wedbush Reiterates Neutral on Biogen, Maintains $121 Price Target

Wedbush analyst Laura Chico reiterates Biogen with a Neutral and maintains $121 price target.

Mantente Actualizado

Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.